Gsk (GSK) Receivables Refunds (2016 - 2025)
Gsk (GSK) has 8 years of Receivables Refunds data on record, last reported at $627.6 million in Q4 2024.
- For Q4 2024, Receivables Refunds rose 35.57% year-over-year to $627.6 million; the TTM value through Dec 2024 reached $627.6 million, up 35.57%, while the annual FY2024 figure was $625.1 million, 34.73% up from the prior year.
- Receivables Refunds reached $627.6 million in Q4 2024 per GSK's latest filing, up from $462.9 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $655.1 million in Q4 2021 and bottomed at $462.9 million in Q4 2023.
- Average Receivables Refunds over 4 years is $555.2 million, with a median of $551.3 million recorded in 2024.
- Peak YoY movement for Receivables Refunds: fell 27.49% in 2022, then surged 35.57% in 2024.
- A 4-year view of Receivables Refunds shows it stood at $655.1 million in 2021, then dropped by 27.49% to $475.0 million in 2022, then fell by 2.54% to $462.9 million in 2023, then soared by 35.57% to $627.6 million in 2024.
- Per Business Quant database, its latest 3 readings for Receivables Refunds were $627.6 million in Q4 2024, $462.9 million in Q4 2023, and $475.0 million in Q4 2022.